SCHEMBL30459459

SCHEMBL30459459

CC(C)Nc1cc(-n2ccc3cc(C#N)cnc32)ncc1C(=O)NC1CCNCC1

nearest known ligand 0.85

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 20/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25221721 1.00 IRAK4 (0.85) IRAK4
SCHEMBL21949093 0.94 IRAK4 (0.89) IRAK4
SCHEMBL21948689 0.93 IRAK4 (0.88) IRAK4
SCHEMBL21949048 0.92 IRAK4 (1.00) IRAK4
SCHEMBL16873208 0.92 IRAK4 (0.85) IRAK4
SCHEMBL16873642 0.92 IRAK4 (1.00) IRAK4
SCHEMBL16873647 0.92 IRAK4 (1.00) IRAK4
SCHEMBL29709746 0.91 IRAK4 (0.84) IRAK4
SCHEMBL24508743 0.91 IRAK4 (0.84) IRAK4
SCHEMBL25649679 0.91 IRAK4 (0.88) IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745138-A1 THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2026-05-20 — — EP disclosed
EP-4678638-A1 NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2026-01-14 — — EP disclosed
CN-120202200-A Oxo-isoindolinyl substituted tetrahydropyrimidinedione-based compounds and applications thereof 标新生物医药科技(上海)有限公司 2025-06-24 — — CN disclosed
WO-2024245443-A1 COMPOUND BASED ON OXOISOINDOLINYL SUBSTITUTED TETRAHYDRO-2-PYRIMIDONE, AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-12-05 — — WO disclosed
EP-4446324-A1 LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2024-10-16 — — EP disclosed
WO-2024188209-A1 NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-09-19 — — WO disclosed
WO-2023104155-A1 LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF 标新生物医药科技(上海)有限公司 2023-06-15 — — WO disclosed
Send feedback